Dexfenfluramine: Difference between revisions
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
m Protected "Dexfenfluramine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 18: | Line 18: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
==Overview== | |||
<!-- Deleted image removed: [[Image:ReduxAd.png|thumb|300px|left|A direct-to-physician advertisement for Redux.]] --> | <!-- Deleted image removed: [[Image:ReduxAd.png|thumb|300px|left|A direct-to-physician advertisement for Redux.]] --> | ||
'''Dexfenfluramine''', also marketed under the name '''Redux''', is a serotoninergic [[anorectic]] drug. It was for some years in the mid-1990s approved by the United States [[Food and Drug Administration]] for the purposes of [[weight loss]]. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by [[sibutramine]], which is a safer alternative to both dexfenfluramine and [[fenfluramine]]. | '''Dexfenfluramine''', also marketed under the name '''Redux''', is a serotoninergic [[anorectic]] drug. It was for some years in the mid-1990s approved by the United States [[Food and Drug Administration]] for the purposes of [[weight loss]]. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by [[sibutramine]], which is a safer alternative to both dexfenfluramine and [[fenfluramine]]. | ||
| Line 34: | Line 33: | ||
*[http://www.fda.gov/cder/news/phen/fenphenpr81597.htm ''FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)''] | *[http://www.fda.gov/cder/news/phen/fenphenpr81597.htm ''FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)''] | ||
[[Category:Drug]] | |||
[[Category:Withdrawn drugs]] | [[Category:Withdrawn drugs]] | ||
[[Category:Serotonin receptor agonists]] | [[Category:Serotonin receptor agonists]] | ||
| Line 39: | Line 39: | ||
{{Antiobesity preparations}} | {{Antiobesity preparations}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
Latest revision as of 19:46, 18 August 2015
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 36% |
| Elimination half-life | 17-20 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C12H16F3N |
| Molar mass | 231.257 g/mol |
|
WikiDoc Resources for Dexfenfluramine |
|
Articles |
|---|
|
Most recent articles on Dexfenfluramine Most cited articles on Dexfenfluramine |
|
Media |
|
Powerpoint slides on Dexfenfluramine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Dexfenfluramine at Clinical Trials.gov Trial results on Dexfenfluramine Clinical Trials on Dexfenfluramine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Dexfenfluramine NICE Guidance on Dexfenfluramine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Dexfenfluramine Discussion groups on Dexfenfluramine Patient Handouts on Dexfenfluramine Directions to Hospitals Treating Dexfenfluramine Risk calculators and risk factors for Dexfenfluramine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Dexfenfluramine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by sibutramine, which is a safer alternative to both dexfenfluramine and fenfluramine.
The drug was manufactured by Interneuron Pharmaceuticals and marketed by Wyeth-Ayerst Laboratories. It is the enantiomer of levofenfluramine.
See also
References
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drug
- Withdrawn drugs
- Serotonin receptor agonists
- Phenethylamines
- Endocrinology